Contrasting Climb Bio (CLYM) & Its Competitors

Climb Bio (NASDAQ:CLYM) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Climb Bio to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.

Volatility & Risk

Climb Bio has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s competitors have a beta of 3.71, indicating that their average share price is 271% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Climb Bio and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7751	21154	48868	1228	2.55

Climb Bio presently has a consensus price target of $10.00, suggesting a potential upside of 412.82%. As a group, “Pharmaceutical preparations” companies have a potential upside of 188.65%. Given Climb Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Climb Bio is more favorable than its competitors.

Valuation & Earnings

This table compares Climb Bio and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.92
Climb Bio Competitors	$9.59 billion	$147.39 million	-5.36

Climb Bio’s competitors have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Climb Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Summary

Climb Bio beats its competitors on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.